Cargando…

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report

TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haiyang, Dong, Xiang, Pan, Xinghe, Ma, Wenliang, Pan, Jun, Guo, Hongqian, Gan, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627181/ https://www.ncbi.nlm.nih.gov/pubmed/37936602 http://dx.doi.org/10.3389/fonc.2023.1252282

Ejemplares similares

Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma
por: Dong, Xiang, et al.
Publicado: (2022)

TFE3-rearranged renal cell carcinoma with osseous metaplasia and indolent behaviour
por: Aldera, Alessandro Pietro, et al.
Publicado: (2022)

TFE3-rearranged renal cell carcinoma with tumour thrombus in the ureter mimicking invasive transitional cell carcinoma
por: Chacko, Arman Z., et al.
Publicado: (2023)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue
por: Xiong, Lei, et al.
Publicado: (2017)

NRF-1 directly regulates TFE3 and promotes the proliferation of renal cancer cells
por: Zhuang, Wenyuan, et al.
Publicado: (2021)

Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients
por: Agizamhan, Sezim, et al.
Publicado: (2018)

Newly Designed Break-Apart and ASPL-TFE3 Dual-Fusion FISH Assay Are Useful in Diagnosing Xp11.2 Translocation Renal Cell Carcinoma and ASPL-TFE3 Renal Cell Carcinoma: A STARD-Compliant Article
por: Chen, Xiancheng, et al.
Publicado: (2015)

The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma
por: Liu, Ning, et al.
Publicado: (2020)

Xp11.2 Translocation Renal Cell Carcinoma With TFE3 Rearrangement: Distinct Morphological Features and Prognosis With Different Fusion Partners
por: Ge, Yan, et al.
Publicado: (2021)

Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma
por: Liu, Ning, et al.
Publicado: (2022)

Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion
por: Wang, Zhen, et al.
Publicado: (2017)

Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies
por: Cheng, Xiangming, et al.
Publicado: (2016)

Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis
por: Liu, Ning, et al.
Publicado: (2016)

LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD(+) kinase-independent manner
por: Chen, Yi, et al.
Publicado: (2023)

Hepatic YAP1-TFE3 Rearranged Epithelioid Hemangioendothelioma
por: Lotfalla, Mira M., et al.
Publicado: (2019)

Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas
por: He, Jian, et al.
Publicado: (2015)

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
por: AbdElhameid, Mohammed K., et al.
Publicado: (2018)

Lingual alveolar soft part sarcoma with absent TFE3 rearrangement
por: Alshahrani, Saeed, et al.
Publicado: (2020)

Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma
por: Guo, Wei, et al.
Publicado: (2023)

Characteristics of peritumoral pseudocapsule in small renal cell carcinoma and its influencing factors
por: Dong, Xiang, et al.
Publicado: (2022)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma
por: Lin, Junyi, et al.
Publicado: (2023)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature
por: Zemankova, Anezka, et al.
Publicado: (2023)

Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements
por: Lee, Seok Joo, et al.
Publicado: (2016)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms
por: Caliò, Anna, et al.
Publicado: (2022)

Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis
por: Murakami, Sho, et al.
Publicado: (2023)

Commentary: High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p
por: Li, Tianhang, et al.
Publicado: (2022)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
por: Bilen, Mehmet A., et al.
Publicado: (2021)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Case Report: TFE3 Positive Xp11.2 Translocation Renal Cell Carcinoma (TRCC) – A Case Study and Review of the Literature
por: Miroński, Ignacy, et al.
Publicado: (2022)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis
por: Qiu, Zhiyu, et al.
Publicado: (2019)

Development and validation of a novel prognostic model for patients with surgically resected esophageal squamous cell carcinoma
por: Hu, Haiyang, et al.
Publicado: (2022)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pk2jamiknrsduvujof94nt7dsk